{"transactions":[{"id":723633,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-29T20:42:45.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date."}],"balance_after":35000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-24","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001849458-26-000001","document":"form4-06292026_080640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1849458/000184945826000001/form4-06292026_080640.xml","form_type":"4"}},{"id":856415,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:15.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":208,"price":325.67,"value":67739.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34297,"source":{"system":"sec-edgar","filing":"0001735276-26-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000060/edgardoc.xml","form_type":"4"}},{"id":856414,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:15.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":272,"price":324.88,"value":88367.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34505,"source":{"system":"sec-edgar","filing":"0001735276-26-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000060/edgardoc.xml","form_type":"4"}},{"id":856413,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:15.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":767,"price":323.84,"value":248385.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":34777,"source":{"system":"sec-edgar","filing":"0001735276-26-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000060/edgardoc.xml","form_type":"4"}},{"id":856412,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:15.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":350,"price":323.01,"value":113053.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":35544,"source":{"system":"sec-edgar","filing":"0001735276-26-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000060/edgardoc.xml","form_type":"4"}},{"id":856411,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:15.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":289,"price":321.82,"value":93005.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":35894,"source":{"system":"sec-edgar","filing":"0001735276-26-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000060/edgardoc.xml","form_type":"4"}},{"id":856410,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:15.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":215,"price":320.81,"value":68974.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36183,"source":{"system":"sec-edgar","filing":"0001735276-26-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000060/edgardoc.xml","form_type":"4"}},{"id":856409,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:15.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":102,"price":320.01,"value":32641.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36398,"source":{"system":"sec-edgar","filing":"0001735276-26-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000060/edgardoc.xml","form_type":"4"}},{"id":856408,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:12:15.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":106,"price":319.03,"value":33817.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36500,"source":{"system":"sec-edgar","filing":"0001735276-26-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000060/edgardoc.xml","form_type":"4"}},{"id":862458,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":10480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":10480,"derivative":{"exercise_price":325.07,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":10480},"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862457,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":37,"price":332.64,"value":12307.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36606,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862456,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":94,"price":331.93,"value":31201.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36643,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862455,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":81,"price":330.85,"value":26798.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36737,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862454,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":170,"price":329.71,"value":56050.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36818,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862453,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":100,"price":328.71,"value":32871.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":36988,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862452,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":329,"price":327.67,"value":107803.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":37088,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862451,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":392,"price":326.81,"value":128109.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":37417,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862450,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":258,"price":325.63,"value":84012.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":37809,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862449,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":90,"price":324.65,"value":29218.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":38067,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862448,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":47,"price":323.62,"value":15210.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":38157,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":862447,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T00:30:06.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":4769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":38204,"source":{"system":"sec-edgar","filing":"0001735276-26-000050","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000050/edgardoc.xml","form_type":"4"}},{"id":874874,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-02T21:09:17.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":false,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date.  On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001735276-26-000039","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000039/edgardoc.xml","form_type":"4"}},{"id":874873,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-02T21:09:17.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":true,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33435,"source":{"system":"sec-edgar","filing":"0001735276-26-000039","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000039/edgardoc.xml","form_type":"4"}},{"id":901556,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T00:27:24.000Z","date":"2026-02-13","kind":"sale","planned":false,"acquired":false,"shares":1959,"price":310.0808,"value":607448.2872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $302.55 to $314.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31769,"source":{"system":"sec-edgar","filing":"0001735276-26-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000027/edgardoc.xml","form_type":"4"}},{"id":901555,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T00:27:24.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting the achievement of non-GAAP operating income for fiscal year 2025 on February 12, 2026, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors."}],"balance_after":33728,"source":{"system":"sec-edgar","filing":"0001735276-26-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000027/edgardoc.xml","form_type":"4"}},{"id":939414,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":15,"price":377.82,"value":5667.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."}],"balance_after":29728,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939413,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":19,"price":375.65,"value":7137.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."}],"balance_after":29743,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939412,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":14,"price":374.44,"value":5242.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29762,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939411,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":2,"price":372.46,"value":744.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29776,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939410,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":19,"price":370.87,"value":7046.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29778,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939409,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":40,"price":369.48,"value":14779.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29797,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939408,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":92,"price":368.62,"value":33913.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29837,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939407,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":41,"price":367.4,"value":15063.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29929,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939406,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":50,"price":366.41,"value":18320.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29970,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939405,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":220,"price":365.56,"value":80423.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30020,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939404,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":199,"price":364.83,"value":72601.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30240,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939403,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":47,"price":363.55,"value":17086.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30439,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939402,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":73,"price":362.38,"value":26453.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30486,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939401,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":98,"price":361.45,"value":35422.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30559,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939400,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":155,"price":360.22,"value":55834.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30657,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939399,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":85,"price":359.14,"value":30526.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30812,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939398,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":123,"price":358.18,"value":44056.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30897,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939397,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":96,"price":357.17,"value":34288.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31020,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939396,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":41,"price":356.09,"value":14599.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31116,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939395,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":42,"price":355.16,"value":14916.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31157,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939394,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":39,"price":353.95,"value":13804.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31199,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":939393,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:22:19.000Z","date":"2026-01-11","kind":"grant","planned":false,"acquired":true,"shares":3800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026."}],"balance_after":31238,"source":{"system":"sec-edgar","filing":"0001735276-26-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527626000012/edgardoc.xml","form_type":"4"}},{"id":1025162,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":1,"price":457.64,"value":457.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."}],"balance_after":27438,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025161,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":70,"price":457.43,"value":32020.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."}],"balance_after":27439,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025160,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":35,"price":455.82,"value":15953.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27509,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025159,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":117,"price":454.84,"value":53216.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27544,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025158,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":157,"price":453.77,"value":71241.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27661,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025157,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":319,"price":452.69,"value":144408.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27818,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025156,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":159,"price":451.86,"value":71845.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28137,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025155,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":260,"price":450.81,"value":117210.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28296,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025154,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":119,"price":449.79,"value":53525.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28556,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025153,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":86,"price":448.77,"value":38594.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28675,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025152,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":27,"price":447.92,"value":12093.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28761,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025151,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":55,"price":446.53,"value":24559.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of PSUs granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28788,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1025150,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-03T21:14:03.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on October 1, 2025."}],"balance_after":28843,"source":{"system":"sec-edgar","filing":"0001735276-25-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000115/edgardoc.xml","form_type":"4"}},{"id":1051757,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-09-02T20:10:42.000Z","date":"2025-08-29","kind":"sale","planned":true,"acquired":false,"shares":144,"price":452.49,"value":65158.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on May 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.22 to $452.54. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25992,"source":{"system":"sec-edgar","filing":"0001735276-25-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000094/edgardoc.xml","form_type":"4"}},{"id":1051756,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-09-02T20:10:42.000Z","date":"2025-08-29","kind":"sale","planned":true,"acquired":false,"shares":266,"price":451.52,"value":120104.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on May 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.21 to $451.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26136,"source":{"system":"sec-edgar","filing":"0001735276-25-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000094/edgardoc.xml","form_type":"4"}},{"id":1051755,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-09-02T20:10:42.000Z","date":"2025-08-29","kind":"sale","planned":true,"acquired":false,"shares":681,"price":449.54,"value":306136.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on May 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.07 to $449.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":26402,"source":{"system":"sec-edgar","filing":"0001735276-25-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000094/edgardoc.xml","form_type":"4"}},{"id":1051754,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-09-02T20:10:42.000Z","date":"2025-08-29","kind":"sale","planned":true,"acquired":false,"shares":1289,"price":448.05,"value":577536.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on May 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.59 to $448.58. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":27083,"source":{"system":"sec-edgar","filing":"0001735276-25-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000094/edgardoc.xml","form_type":"4"}},{"id":1051753,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-09-02T20:10:42.000Z","date":"2025-08-29","kind":"sale","planned":true,"acquired":false,"shares":899,"price":446.98,"value":401835.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on May 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.34 to $447.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28372,"source":{"system":"sec-edgar","filing":"0001735276-25-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000094/edgardoc.xml","form_type":"4"}},{"id":1051752,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-09-02T20:10:42.000Z","date":"2025-08-29","kind":"sale","planned":true,"acquired":false,"shares":195,"price":445.53,"value":86878.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on May 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $445.32 to $445.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29271,"source":{"system":"sec-edgar","filing":"0001735276-25-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000094/edgardoc.xml","form_type":"4"}},{"id":1062577,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":12,"price":455.82,"value":5469.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29466,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1062576,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":241,"price":454.84,"value":109616.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29478,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1062575,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":543,"price":454.04,"value":246543.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":29719,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1062574,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":329,"price":452.96,"value":149023.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30262,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1062573,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":103,"price":451.99,"value":46554.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30591,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1062572,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":39,"price":450.92,"value":17585.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30694,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1062571,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":90,"price":449.92,"value":40492.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30733,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1062570,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":39,"price":447.98,"value":17471.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":30823,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1062569,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-08-19T21:28:18.000Z","date":"2025-08-15","kind":"grant","planned":false,"acquired":true,"shares":2851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025."}],"balance_after":30862,"source":{"system":"sec-edgar","filing":"0001735276-25-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000091/edgardoc.xml","form_type":"4"}},{"id":1098911,"issuer":{"id":5687,"kind":"organization","name":"Lexeo Therapeutics, Inc.","symbol":"LXEO"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T21:00:20.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date."}],"balance_after":14583,"derivative":{"exercise_price":4.18,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":14583},"source":{"system":"sec-edgar","filing":"0001415889-25-018524","document":"form4-06302025_050616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1849458/000141588925018524/form4-06302025_050616.xml","form_type":"4"}},{"id":1223348,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2025-03-05T21:22:22.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":7819,"derivative":{"exercise_price":243.53,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":7819},"source":{"system":"sec-edgar","filing":"0001735276-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000033/edgardoc.xml","form_type":"4"}},{"id":1223347,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:22:22.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":3,"price":247.35,"value":742.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.04 to $247.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28011,"source":{"system":"sec-edgar","filing":"0001735276-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000033/edgardoc.xml","form_type":"4"}},{"id":1223346,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:22:22.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":29,"price":246.18,"value":7139.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $246.00 to $246.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28014,"source":{"system":"sec-edgar","filing":"0001735276-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000033/edgardoc.xml","form_type":"4"}},{"id":1223345,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:22:22.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":70,"price":245.26,"value":17168.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.91 to $245.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28043,"source":{"system":"sec-edgar","filing":"0001735276-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000033/edgardoc.xml","form_type":"4"}},{"id":1223344,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:22:22.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":96,"price":244.41,"value":23463.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28113,"source":{"system":"sec-edgar","filing":"0001735276-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000033/edgardoc.xml","form_type":"4"}},{"id":1223343,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:22:22.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":142,"price":243.36,"value":34557.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.89 to $243.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28209,"source":{"system":"sec-edgar","filing":"0001735276-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000033/edgardoc.xml","form_type":"4"}},{"id":1223342,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:22:22.000Z","date":"2025-03-03","kind":"sale","planned":false,"acquired":false,"shares":131,"price":242.37,"value":31750.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.87 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":28351,"source":{"system":"sec-edgar","filing":"0001735276-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000033/edgardoc.xml","form_type":"4"}},{"id":1223341,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:22:22.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":14137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person has reported certain prior awards of RSUs in Table II of Form 4.  The total reported in Column 5 includes the 14,137 newly awarded RSUs and 13,874 shares of common stock.  The Reporting Person also holds 1,666 unvested RSUs that were previously reported in Table II."}],"balance_after":28482,"source":{"system":"sec-edgar","filing":"0001735276-25-000033","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000033/edgardoc.xml","form_type":"4"}},{"id":1236438,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":false,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date.  On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date.  On February 27, 2025, the second tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4."}],"balance_after":1666,"derivative":{"underlying":"Common Stock","underlying_shares":1667},"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236437,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":38,"price":244.11,"value":9276.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14345,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236436,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":78,"price":243.23,"value":18971.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.87 to $243.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14383,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236435,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":192,"price":242.44,"value":46548.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.86 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14461,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236434,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":82,"price":241.51,"value":19803.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.85 to $241.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14653,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236433,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":50,"price":240.32,"value":12016.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $239.82 to $240.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14735,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236432,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":23,"price":239.18,"value":5501.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.73 to $239.69. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14785,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236431,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":22,"price":238.33,"value":5243.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $237.72 to $238.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14808,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236430,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-28","kind":"sale","planned":false,"acquired":false,"shares":28,"price":236.51,"value":6622.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $236.50 to $237.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14830,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1236429,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-03T21:31:31.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":true,"shares":1667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14858,"source":{"system":"sec-edgar","filing":"0001735276-25-000021","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000021/edgardoc.xml","form_type":"4"}},{"id":1349770,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-11-27T22:21:00.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":84,"price":252.27,"value":21190.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.09  to $252.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13191,"source":{"system":"sec-edgar","filing":"0001735276-24-000105","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000105/edgardoc.xml","form_type":"4"}},{"id":1349769,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-11-27T22:21:00.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":826,"price":251.42,"value":207672.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.07  to $252.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13275,"source":{"system":"sec-edgar","filing":"0001735276-24-000105","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000105/edgardoc.xml","form_type":"4"}},{"id":1349768,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-11-27T22:21:00.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":318,"price":250.68,"value":79716.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.05  to $251.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14101,"source":{"system":"sec-edgar","filing":"0001735276-24-000105","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000105/edgardoc.xml","form_type":"4"}},{"id":1349767,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-11-27T22:21:00.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":215,"price":249.6,"value":53664.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.00  to $250.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14419,"source":{"system":"sec-edgar","filing":"0001735276-24-000105","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000105/edgardoc.xml","form_type":"4"}},{"id":1349766,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-11-27T22:21:00.000Z","date":"2024-11-26","kind":"sale","planned":false,"acquired":false,"shares":26,"price":247.77,"value":6442.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.76  to $248.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14634,"source":{"system":"sec-edgar","filing":"0001735276-24-000105","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000105/edgardoc.xml","form_type":"4"}},{"id":1349765,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":34717,"kind":"person","name":"Tanguler Tolga","position":1,"cik":"0001849458","reported_name":"Tanguler Tolga","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-11-27T22:21:00.000Z","date":"2024-11-25","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024."}],"balance_after":14660,"source":{"system":"sec-edgar","filing":"0001735276-24-000105","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000105/edgardoc.xml","form_type":"4"}}],"next_cursor":"2024-11-27T22:21:00.000000Z,1349765"}